AU2014207311A1 - Oligooxopiperazines for p53 reactivation - Google Patents

Oligooxopiperazines for p53 reactivation Download PDF

Info

Publication number
AU2014207311A1
AU2014207311A1 AU2014207311A AU2014207311A AU2014207311A1 AU 2014207311 A1 AU2014207311 A1 AU 2014207311A1 AU 2014207311 A AU2014207311 A AU 2014207311A AU 2014207311 A AU2014207311 A AU 2014207311A AU 2014207311 A1 AU2014207311 A1 AU 2014207311A1
Authority
AU
Australia
Prior art keywords
aryl
alkyl
formula
arylalkyl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2014207311A
Other languages
English (en)
Inventor
Paramjit S. Arora
Anna Mapp
Quintin PAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan System
New York University NYU
Ohio State University Research Foundation
Original Assignee
University of Michigan System
New York University NYU
Ohio State University Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan System, New York University NYU, Ohio State University Research Foundation filed Critical University of Michigan System
Publication of AU2014207311A1 publication Critical patent/AU2014207311A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2014207311A 2013-01-19 2014-01-21 Oligooxopiperazines for p53 reactivation Abandoned AU2014207311A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361754575P 2013-01-19 2013-01-19
US61/754,575 2013-01-19
PCT/US2014/012337 WO2014113794A2 (en) 2013-01-19 2014-01-21 Oligooxopiperazines for p53 reactivation

Publications (1)

Publication Number Publication Date
AU2014207311A1 true AU2014207311A1 (en) 2015-08-20

Family

ID=51207874

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014207311A Abandoned AU2014207311A1 (en) 2013-01-19 2014-01-21 Oligooxopiperazines for p53 reactivation

Country Status (7)

Country Link
US (1) US9695153B2 (enExample)
EP (1) EP2945631A4 (enExample)
JP (1) JP2016510327A (enExample)
CN (1) CN105246481A (enExample)
AU (1) AU2014207311A1 (enExample)
CA (1) CA2898329A1 (enExample)
WO (1) WO2014113794A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015264201A1 (en) 2014-05-21 2017-01-12 New York University Oxopiperazine helix mimetics for control of hypoxia-inducible gene expression
PE20181953A1 (es) 2016-03-02 2018-12-17 Eisai Randd Man Co Ltd Conjugados de anticuerpo y farmaco basados en eribulina y metodos para su uso
JP7300394B2 (ja) 2017-01-17 2023-06-29 ヘパリジェニックス ゲーエムベーハー 肝再生の促進又は肝細胞死の低減もしくは予防のためのプロテインキナーゼ阻害
SG11202005365WA (en) 2017-12-15 2020-07-29 Inthera Bioscience AG 1 -(piperidinocarbonylmethyl)-2-oxopiperazine derivatives for treating cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3542230A1 (de) 1985-11-29 1987-06-04 Bayer Ag Verfahren zur herstellung von oligomeren und telechelen mit carboxy-piperazin-einheiten und neue oligomere und telechele des poly(carboxypiperazins)
GB9022790D0 (en) 1990-10-19 1990-12-05 Wyeth John & Brother Ltd Piperazine derivatives
EE9700141A (et) 1994-12-23 1997-12-15 Dr. Karl Thomae Gmbh Piperasiinderivaadid, neid sisaldavad ravimid, nende kasutamine ja valmistamise meetod
FR2803594B1 (fr) 2000-01-11 2002-07-19 Centre Nat Rech Scient Oligomeres de mimes contraints non peptidiques de dipeptides ou de tripeptides, et leurs utilisations
KR100464261B1 (ko) 2002-01-24 2005-01-03 주식회사 파나진 Ｐｎａ 올리고머를 합성하기 위한 신규한 단량체 및 그의제조방법
US6841675B1 (en) 2002-06-13 2005-01-11 The Regents Of The University Of California Piperazine-based nucleic acid analogs
KR100962301B1 (ko) * 2006-11-03 2010-06-11 재단법인서울대학교산학협력재단 자궁경부암을 위한 치료용 조성물
WO2009097486A1 (en) 2008-01-31 2009-08-06 The Scripps Research Institute OXAZOLE-PYRROLE-PIPERAZINE α-HELIX MIMETIC
ES2446249T3 (es) * 2008-09-18 2014-03-06 New York University Inhibición de la interación entre hif-1a y p300/cbp con hélices basadas en sustitutos de los enlaces de hidrógeno
WO2012021144A1 (en) * 2010-08-12 2012-02-16 New York University Oligooxopiperazines and methods of making and using them
CN104334541A (zh) * 2012-02-16 2015-02-04 纽约大学 使用低聚氧代哌嗪非肽螺旋模拟物对低氧诱导基因表达的控制

Also Published As

Publication number Publication date
CA2898329A1 (en) 2014-07-24
WO2014113794A3 (en) 2014-09-12
US20140205655A1 (en) 2014-07-24
WO2014113794A2 (en) 2014-07-24
JP2016510327A (ja) 2016-04-07
EP2945631A2 (en) 2015-11-25
US9695153B2 (en) 2017-07-04
CN105246481A (zh) 2016-01-13
EP2945631A4 (en) 2016-06-29

Similar Documents

Publication Publication Date Title
US9605026B2 (en) Hydrogen-bond surrogate peptides and peptidomimetics for p53 reactivation
US11220532B2 (en) Targeting deregulated Wnt signaling in cancer using stabilized alpha-helices of BCL-9
US20220363666A1 (en) Tyrosine kinase inhibitor compositions, methods of making and methods of use
JP7307744B2 (ja) がん治療のための１－（ピペリジノカルボニルメチル）－２－オキソピペラジン誘導体
TW202136252A (zh) 化合物及其用途
CA3133688A1 (en) Compositions and methods for treating cancer
US20240368224A1 (en) Bicyclic peptidyl pan-ras inhibitors
CA3218805A1 (en) Compositions and methods for intracellular therapeutics
JP2020536096A (ja) 腫瘍成長を阻害するための材料および方法
CA3021550A1 (en) Pyrazolopyrimidine compounds, compositions comprising the same and their use as tyrosine kinase inhibitors
US9695153B2 (en) Oligooxopiperazines for p53 reactivation
US20220041613A1 (en) Tyrosine kinase inhibitor compositions, methods of making and methods of use
US10882863B2 (en) Compounds for reducing c-Myc in c-Myc overexpressing cancers background
WO2022015670A1 (en) Pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cyclin-dependent kinase 2 inhibitors
US12281180B2 (en) Peptoid-peptide macrocycles, pharmaceutical compositions and methods of using the same
US20230064189A1 (en) 1h-pyrazolo[3,4-d]pyrimidine compounds useful for the treatment of platinum-resistant cancer
KR102053933B1 (ko) Trap1 저해제로서 유용한 화합물 및 이를 포함하는 항암용 조성물
CA3140026A1 (en) Polypeptides for treatment of cancer
WO2013090991A1 (en) Tgf-beta therapy
US20230003732A1 (en) Method for treating cancer
CA3208598A1 (en) Novel bicyclic peptides
WO2015192052A1 (en) Egfr targeting compounds and methods of use thereof
HK40080608A (en) Compounds and uses thereof
AU2010291878A1 (en) Cytotoxic compounds

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted